-
Mashup Score: 7
Electronic nose (E-nose) technology has demonstrated excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
Pathologic response (PathR) by histopathological assessment of resected specimens, may be an early clinical endpoint associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve efficiency and precision of PathR assessment. LCMC3 (NCT02927301) evaluated neoadjuvant atezolizumab in patients with resectable non-small cell lung cancer (NSCLC) and reported 20% major pathologic response rate.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 8Lung Cancer in Brunei Darussalam - 4 day(s) ago
Brunei, the abode of peace, is known for its rich cultural heritage, with a monarchy that serves as the head of the state and government. It is one of the world’s smallest countries and is located on Borneo Island and is part of the Southeast Asian countries. This small island nation is surrounded by the South China Sea in the north and on all other sides by the Malaysian state of Sarawak (Fig. 1). Brunei is known for its rainforests, which cover 78% of the country, and houses the largest palace in the world (Guinness Book of World Records).
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) demonstrated that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cut-off: 16 January 2023).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 59
Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) demonstrated that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cut-off: 16 January 2023).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 15 day(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 15 day(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib. - 19 day(s) ago
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pre-treatment and on-treatment circulating tumor DNA (ctDNA), as well as treatment-emergent alterations upon disease progression.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
Lung cancer screening using low-dose computed tomography (LDCT) carefully implemented has been found to reduce deaths from lung cancer. Optimal management starts with selection of eligibility criteria, counseling of screenees, smoking cessation, selection of the regimen of screening which specifies the imaging protocol, and workup of LDCT findings. Coordination of clinical, radiologic, and interventional teams and ultimately treatment of diagnosed lung cancers under screening determine the benefit of LDCT screening.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 65Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the ITMIG/ESTS Database - 22 day(s) ago
R0 resection and radiation therapy have been associated with improved OS in thymic carcinoma (TC) patients. Here we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
Electronic nose tech uses exhaled volatile organic compounds and is being studied as a way to detect early stage lung cancers. Report of E-nose performance in pts with suspected stage I NSCLC @JTOonline shows promise. Can this complement CT screening? https://t.co/zvbOkilK4g